| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| SABER Study for Selected Early Stage Breast Cancer | N/A | University of Miami | <1 mi |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Tubulis GmbH | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | <1 mi |
| A Study of Breast Cancer Risk Factors and Outcomes of People in Florida | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | — | Adela, Inc | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| Precise Oncology Interventions in Nutrition and Training (OnPoint) | N/A | University of Miami | <1 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | <1 mi |
| Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences | N/A | University of Miami | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | Phase 1/2 | SynDevRx, Inc. | <1 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | <1 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | <1 mi |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Breast Re-irradiation After Second Ipsilateral Lumpectomy | N/A | Youssef Zeidan | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC | Phase 2 | Reshma L. Mahtani, D.O. | <1 mi |
| Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy | Phase 3 | Proton Collaborative Group | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | Phase 2 | ALX Oncology Inc. | <1 mi |
| Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer | N/A | University of Miami | <1 mi |
| Women Informed to Screen Depending on Measures of Risk (Wisdom Study) | N/A | University of California, San Francisco | <1 mi |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase 3 | AstraZeneca | <1 mi |
| A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials | — | University of Florida | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | LeonaBio | <1 mi |
| A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer | N/A | University of Miami | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Phase 2 | Sarah Sammons, MD | <1 mi |
| With Love, Grandma ("Con Cariño, Abuelita") Pilot Study | N/A | University of Miami Sylvester Comprehensive Cancer Center | <1 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | <1 mi |
| A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients | Phase 4 | Jonsson Comprehensive Cancer Center | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | N/A | Natera, Inc. | <1 mi |
| Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer | Phase 3 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | 4 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | 4 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | 4 mi |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | 4 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | 4 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 4 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | 4 mi |
| AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc | N/A | Columbia University | 4 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 4 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 4 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 4 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | 6 mi |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 6 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | 6 mi |
| Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM) | N/A | University of Miami | 6 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | 9 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 9 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 9 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | 9 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 17 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | 17 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | 17 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 17 mi |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | 17 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 25 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | 25 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 2 | Pfizer | 25 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | 26 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | 26 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | 26 mi |
| Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 26 mi |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | 26 mi |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | 26 mi |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Phase 4 | AstraZeneca | 26 mi |
| Global Cardio Oncology Registry | — | The Cleveland Clinic | 27 mi |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | 27 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 27 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | 31 mi |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Phase 1 | Compass Therapeutics | 33 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | 42 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | 42 mi |
| Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors | N/A | Florida Atlantic University | 42 mi |